Private company

MusclePharm Corp

MusclePharm Corp is an American pharmaceutical preparations company, incorporated in Nevada.1 It is headquartered in Denver, Colorado.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersDenver, Colorado1
  • Incorporated inNV2
  • Business address4721 Ironton Street, Denver, Co 802392
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

10.7%Gross margin3
-17.8%Operating margin3
-25.7%Net margin3
-22.3%Revenue growth, 20213
-$8.0MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Cost of revenue89¢$44.7M
  • Interest11¢$5.5M
  • Income tax0¢$8.0K

Out of $50.0M in revenue.3 The company lost money this year.

Financial statements

Revenue45673$50.0M in 2021−70% since 2015
0$50.0M$100.0M$150.0M$200.0M2015: $166.9M$166.9M20152016: $132.5M$132.5M2016−21%2017: $93.6M$93.6M2017−29%2018: $88.1M$88.1M2018−6%2019: $79.7M$79.7M2019−10%2020: $64.4M$64.4M2020−19%2021: $50.0M$50.0M2021−22%
Gross profit45673$5.4M in 2021−91% since 2015
0$20.0M$40.0M$60.0M2015: $56.9M$56.9M20152016: $44.5M$44.5M2016−22%2017: $22.9M$22.9M2017−48%2018: $18.4M$18.4M2018−20%2019: $8.7M$8.7M2019−53%2020: $19.6M$19.6M2020+126%2021: $5.4M$5.4M2021−73%
Operating income45673-$8.9M in 2021−82% since 2015
-$60.0M-$40.0M-$20.0M0$20.0M2015: -$49.9M-$49.9M20152016: -$8.7M-$8.7M2016−83%2017: -$6.6M-$6.6M2017−23%2018: -$7.8M-$7.8M2018+18%2019: -$15.1M-$15.1M2019+93%2020: $2.6M$2.6M20202021: -$8.9M-$8.9M2021
Net income45673-$12.9M in 2021−75% since 2015
-$60.0M-$40.0M-$20.0M0$20.0M2015: -$51.9M-$51.9M20152016: -$3.5M-$3.5M2016−93%2017: -$12.5M-$12.5M2017+260%2018: -$10.8M-$10.8M2018−14%2019: -$18.9M-$18.9M2019+76%2020: $3.2M$3.2M20202021: -$12.9M-$12.9M2021
Fiscal year2015201620172018201920202021
Revenue$166.9M4$132.5M5$93.6M6$88.1M6$79.7M7$64.4M3$50.0M3
Cost of revenue$109.9M4$88.0M5$70.6M6$69.7M6$71.0M7$44.8M3$44.7M3
Gross profit$56.9M4$44.5M5$22.9M6$18.4M6$8.7M7$19.6M3$5.4M3
Research and development$4.3M4$1.9M5$642.0K6$751.0K6$893.0K6
Selling, general and admin$19.4M4$15.9M5$13.6M6$11.6M6$9.8M7$7.1M7
Operating expenses$14.3M3
Operating income-$49.9M4-$8.7M5-$6.6M6-$7.8M6-$15.1M7$2.6M3-$8.9M3
Interest$3.8M6$3.9M6$3.6M7$1.5M3$5.5M3
Income before tax-$12.9M3
Income tax$105.0K4$318.0K5$142.0K6$100.0K6$86.0K7-$19.0K3-$8.0K3
Net income-$51.9M4-$3.5M5-$12.5M6-$10.8M6-$18.9M7$3.2M3-$12.9M3
Earnings per share-$0.927$0.103-$0.393
Earnings per share (diluted)-$0.927$0.073-$0.393
Shares (weighted, basic)33.4M shares3
Shares (weighted, diluted)33.4M shares3

Compare MusclePharm Corp with another company

Corporate structure

MusclePharm Corp sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of MusclePharm Corp

  • White Winston Select Asset Fund Series Fund MP-18, LLC Filed SC 13D/A on MusclePharm Corp, latest Dec 21, 2022 (3 filings since Feb 22, 2022)
  • MusclePharm Corp Denver, Colorado

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What MusclePharm Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$72.0K3 Dec 31, 2021$206.0K3 Dec 31, 2020−65.0%
Accumulated depreciation$67.0K3 Dec 31, 2021$193.0K3 Dec 31, 2020−65.3%
Property and equipment, net$5.0K3 Dec 31, 2021$13.0K3 Dec 31, 2020−61.5%
Operating-lease assets (leased space)$203.0K3 Dec 31, 2021$474.0K3 Dec 31, 2020−57.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.2M3 Dec 31, 2021$2.0M3 Dec 31, 2020−38.9%

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, gross$2.2M3 Dec 31, 2021$2.2M3 Dec 31, 20200%
Accumulated amortization-$2.2M3 Dec 31, 2021-$1.9M3 Dec 31, 2020−17.0%
Finite-lived intangibles, net$35.0K3 Dec 31, 2021$356.0K3 Dec 31, 2020−90.2%

Inventory

ItemLatestA year beforeChange
Inventory, total$1.8M3 Dec 31, 2021$1.0M3 Dec 31, 2020+77.3%
Raw materials$694.0K3 Dec 31, 2021$437.0K3 Dec 31, 2020+58.8%
Finished goods$1.1M3 Dec 31, 2021$700.0K3 Dec 31, 2020+63.4%

Leadership

Who has led MusclePharm Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ryan Charles Drexler2019–2021

Chair

  1. Ryan Charles Drexler2016

President

  1. Cory J. Gregory2010–2012
  2. Richard Estalella2014
  3. Ryan Charles Drexler2020
  4. Sabina Rizvi2022

Chief financial officer

  1. Todd Edwin Huss2010
  2. Lawrence S. Meer2010
  3. Don Prosser2014
  4. John C. Price2015
  5. Sabina Rizvi2022

Chief operating officer

  1. Leonard K. Armenta Jr.2010
  2. Michael Shawn Wingate2010
  3. John H. Bluher2012–2013
  4. Richard Estalella2013
201520202025
Board members and other officers (25)

Former names

  • Tone in TwentyNov 2, 2007 to Feb 25, 20102

Timeline

  1. Aug 31, 20238-K Executive or director change45
  2. Jul 19, 20238-K Executive or director change46
  3. Mar 10, 20238-K Executive or director change47
  4. Jan 11, 20238-K Change of auditor48
  5. Jan 11, 20238-K Bankruptcy or receivership49
  6. Jan 9, 20238-K Bankruptcy or receivership50
  7. Sep 29, 20228-K Executive or director change51
  8. Sep 19, 20228-K Debt or obligation accelerated52
  9. Aug 23, 20228-K Executive or director change53
  10. Aug 22, 20228-K Earlier financial statements no longer reliable54
  11. Jul 28, 20228-K Executive or director change55
  12. Jul 12, 20228-K Executive or director change56
  13. Sep 20, 2019New chief executive Ryan Charles Drexler becomes CEO9

Filings

44 filings to the SEC since October 2021: 2 annual reports, 2 quarterly reports, 25 major events, 4 insider forms, 3 large holders, 8 other. The latest 20:

  1. Mar 28, 2025SEC STAFF ACTION EDGAR
  2. Mar 11, 2025REVOKED EDGAR
  3. Aug 31, 20238-K EDGAR
  4. Jul 19, 20238-K EDGAR
  5. Mar 10, 20238-K EDGAR
  6. Jan 11, 20238-K 8K EDGAR
  7. Jan 11, 20238-K 8K CHANGE IN REGISTRANT EDGAR
  8. Jan 9, 20238-K EDGAR
  9. Dec 21, 2022SC 13D/A EDGAR
  10. Sep 29, 20228-K EDGAR
  11. Sep 19, 20228-K EDGAR
  12. Aug 23, 20228-K EDGAR
  13. Aug 22, 20228-K EDGAR
  14. Aug 17, 2022NT 10-Q EDGAR
  15. Jul 28, 20228-K EDGAR
  16. Jul 28, 20224 EDGAR
  17. Jul 28, 20223 EDGAR
  18. Jul 12, 20228-K EDGAR
  19. Jun 22, 20223 EDGAR
  20. Jun 22, 20228-K EDGAR

The 44 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 0 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 29, 2022Enright Todd M.10% ownerSale626,826Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How MusclePharm Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMusclePharm Corp1
  • CIK0001415684
  • Employer ID (EIN)77-06641931
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inNevada1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address4721 Ironton Street, Denver, CO 802391
  • Phone(800) 210-73691
  • Shares outstanding34,348,891 as of May 10, 20228
  • Public float$33.2M as of Jun 30, 20213
  • On EDGAR sinceNov 2, 20071
  • Filings714 in all: 8-K (218), 4 (137), 10-Q (41), 3 (34), SC 13D/A (32), UPLOAD (26), CORRESP (23), 10-Q/A (14)1
    All 43 form types

    10-K (13), EFFECT (13), S-1/A (12), 8-K/A (11), D (11), POS AM (11), 424B3 (10), NT 10-Q (10), SC 13G (10), 10-K/A (9), SC 13G/A (9), SC 13D (8), DEF 14A (7), NT 10-K (7), S-1 (7), DEF 14C (6), PRE 14C (6), 4/A (4), 10QSB (3), 8-A12G (2), DEFA14A (2), PRE 14A (2), PRER14C (2), SB-2/A (2), SEC STAFF LETTER (2), 3/A (1), 424B4 (1), CT ORDER (1), POS EX (1), REVOKED (1), RW (1), S-8 (1), SB-2 (1), SC 14F1 (1), SEC STAFF ACTION (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2022
    Quarterly report (10-Q) May 16, 2022
    Proxy statement (DEF 14A) Oct 26, 2018
    Latest 8-K (8-K) Aug 31, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57